Amgen Aktie News

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.

Generating passive income is great for investors, and holding dividend-paying stocks is an excellent way to do that. However, not all corporations that pay dividends will be attractive to income seekers.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration and patent cliff risks, supporting Amgen's stability as a portfolio anchor. Biosimilars face execution, pricing, and demand risks, but continu...

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.

Following quite encouraging news from the laboratory on Monday, Amgen (AMGN 4.07%) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development.

Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif. , June 30, 2025 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall...

Over the past year, Apple (AAPL 0.04%) and Amgen (AMGN -0.69%), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds. Apple is struggling due to the threat that President Donald Trump's trade agenda poses to its business, while Amgen faced a clinical setback late last year.